What did the FDA approve for inherited deafness?

FDA approves first gene therapy for inherited deafness

The FDA has approved the first-ever gene therapy for inherited deafness, a milestone for treatments that target the underlying cause of certain genetic hearing-loss conditions.

Coverage indicates the therapy was developed by Regeneron and is described as a gene therapy for people who were born with a rare form of deafness. While it may benefit only a limited patient population because the condition is uncommon, the approval is still significant because it broadens the list of FDA-authorized gene therapies from rare monogenic disorders to a new sensory target.

Why the approval matters

Gene therapies work by delivering genetic material to help restore function—here, the goal is restoring hearing rather than managing symptoms. Approving such a treatment requires evidence that the benefits outweigh the risks, including safety monitoring for delivery-related and long-term effects.

What happens next

After approval, patients and clinicians will look for guidance on:

• Eligibility criteria for the specific inherited form of deafness
• How and where treatment is delivered
• Longer-term follow-up to understand durability of hearing improvements and any delayed adverse events

Overall, the decision marks a landmark step in translating gene-editing and gene-delivery science into a therapy with a concrete functional outcome for patients born with a genetic hearing disorder.